Keros Therapeutics (KROS) Return on Capital Employed (2020 - 2025)
Keros Therapeutics (KROS) reported Return on Capital Employed of 12.99% for Q4 2025, up 4997.0% on a YoY basis from 0.25% in Q4 2024, and up 116.41% quarter-over-quarter from 6.0% in Q3 2025.
Keros Therapeutics (KROS) Return on Capital Employed (2020 - 2025) Analysis & Trends
Keros Therapeutics has reported Return on Capital Employed for 6 years, with the latest figure at 12.99% in Q4 2025.
- For the quarter ending Q4 2025, Return on Capital Employed rose 4997.0% year-over-year to 12.99%; the trailing twelve-month figure through Dec 2025 stood at 12.99% (up 4997.0% YoY), and the FY2025 full-year result was 14.8%, up 6009.0% from the prior year.
- Return on Capital Employed for Q4 2025 stood at 12.99%, up from 6.0% in the prior quarter.
- The five-year high for Return on Capital Employed was 12.99% in Q4 2025, with the low at 52.49% in Q4 2023.
- Historically, Return on Capital Employed has averaged 28.5% across 5 years, with a median of 37.04% in 2022.
- Annual changes were most pronounced in 2022 — Return on Capital Employed tumbled 1920 bps — and 2025, when it surged 4997 bps.
- Keros Therapeutics' Return on Capital Employed stood at 24.43% in 2021, then sank by 79 bps to 43.63% in 2022, then slipped by 20 bps to 52.49% in 2023, then gained by 30 bps to 36.98% in 2024, then soared by 135 bps to 12.99% in 2025.
- The last three Return on Capital Employed figures came in at 12.99% (Q4 2025), 6.0% (Q3 2025), and 0.04% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -107.40% |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -50.43% |
| 10 | Keros Therapeutics | 378.54 Mn | 91.14 Mn | - | 12.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 12.99% |
| Sep 30, 2025 | 6.00% |
| Jun 30, 2025 | 0.04% |
| Mar 31, 2025 | -1.56% |
| Dec 31, 2024 | -36.98% |
| Sep 30, 2024 | -41.80% |
| Jun 30, 2024 | -42.00% |
| Mar 31, 2024 | -43.88% |
| Dec 31, 2023 | -52.49% |
| Sep 30, 2023 | -47.89% |
| Jun 30, 2023 | -39.56% |
| Mar 31, 2023 | -39.23% |
| Dec 31, 2022 | -43.63% |
| Sep 30, 2022 | -38.45% |
| Jun 30, 2022 | -37.09% |
| Mar 31, 2022 | -27.72% |
| Dec 31, 2021 | -24.43% |
| Sep 30, 2021 | -28.71% |
| Jun 30, 2021 | -23.27% |
| Mar 31, 2021 | -20.39% |